Bavarian Nordic inks another major vaccine contract with Canada – Endpoints News

As mon­key­pox cas­es con­tin­ue to af­fect na­tions in North Amer­i­ca and across the globe, Cana­da is look­ing to step up its pre­ven­tion ef­forts via a boost­ed con­tract with Bavar­i­an Nordic.
The Pub­lic Health Agency of Cana­da (PHAC) an­nounced on Tues­day that it has changed its con­tract with the Dan­ish drug­mak­er. The agree­ment will see Bavar­i­an Nordic de­liv­er its Jyn­neos vac­cine, al­so known as Im­va­mune, to the PHAC at a val­ue of $234 mil­lion, in ad­di­tion to $180 mil­lion in con­tract op­tions span­ning 10 years.
This move ex­tends an orig­i­nal five-year, $56 mil­lion con­tract with Bavar­i­an Nordic that was grant­ed in June to a to­tal val­ue of $470 mil­lion. The bulk of the de­liv­ery is ex­pect­ed next year; how­ev­er, the ex­act amount of dos­es to be shipped was not dis­closed.
An­oth­er con­tract has al­so been grant­ed to Cana­da’s De­part­ment of Na­tion­al De­fense, with a $2 mil­lion val­ue and $18 mil­lion in ad­di­tion­al op­tions avail­able.
“As a trust­ed sup­pli­er of small­pox vac­cines to the Cana­di­an au­thor­i­ties since 2008, we are pleased to ex­tend and ex­pand our col­lab­o­ra­tion for the next decade, thus help­ing to main­tain the readi­ness for Cana­da to re­spond quick­ly to emer­gen­cies, such as the cur­rent mon­key­pox out­break,” said Bavar­i­an Nordic CEO Paul Chap­lin in a state­ment.
The deal al­so comes at a time when the mon­key­pox case count in Cana­da sits north of 1,300 cas­es, ac­cord­ing to the CDC. How­ev­er, in a re­port from the CBC, WHO Gen­er­al Di­rec­tor Tedros Ad­hanom Ghe­breye­sus said that cas­es in Cana­da were be­gin­ning to show a “sus­tained down­ward trend” main­ly due to pub­lic health ini­tia­tives. Sim­i­lar down­ward trends have been ob­served in the US too.
The move al­so gave Bavar­i­an Nordic $BA­VA a 6% raise to­day in its share price. How­ev­er, the com­pa­ny is still fac­ing a 44% drop in its share price from last year, de­spite a bump at the be­gin­ning of the mon­key­pox out­break.
In the US, where cas­es sit well above 23,000 since the out­break be­gan, Bavar­i­an Nordic’s man­u­fac­tur­ing fa­cil­i­ty in Den­mark was giv­en a thumbs-up from the FDA to ex­pand pro­duc­tion this sum­mer. And in or­der to get US pro­duc­tion go­ing even fur­ther, CD­MO Grand Riv­er Asep­tic Man­u­fac­tur­ing nabbed a deal with Bavar­i­an Nordic to fill and fin­ish the vac­cine for wider US dis­tri­b­u­tion.
APAC is the fastest growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies globally, with China leading in the region. 
APAC is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022. The number of CAR-T trials initiated by Western companies has rapidly increased in recent years (current CAGR of about 60%), with multiple targets being explored including CD19, CD20, CD22, BCMA, CD30, CD123, CD33, CD38, and CD138.
Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world.
In the months since, we’ve seen the natural Darwinian down cycle take effect. Reverse mergers made a comeback, with more burned out shells to go public at a time IPOs and road shows are out of favor. And no doubt some of the more recent arrivals on the investing side of the business are finding greener pastures.
Unlock this article along with other benefits by subscribing to one of our paid plans.
Weeks after announcing the spinoff of generics arm Sandoz, Vas Narasimhan paints a picture of the new, slimmer Novartis — with a “US-first mindset,” he said at an investor event on Thursday.
The CEO unveiled ambitious plans to become a top-five player in the US by 2027 at Novartis’ “Meet the Management” event in Basel, Switzerland, which means ramping up clinical trials in the states and “building capability and talent, among other things.” The company’s also shooting for a top-three ranking in China.
Unlock this story instantly and join 150,600+ biopharma pros reading Endpoints daily — and it’s free.
ODAC on Thursday voted overwhelmingly against keeping the accelerated approval for Sweden-based Oncopeptides’ Pepaxto, voting 14 “no,” and 2 “yes” to the FDA’s question of: “is the benefit-risk profile of melphalan flufenamide favorable for the currently indicated patient population?”
It’s been more than 15 months since Oncopeptides first presented to the FDA its failed results from a confirmatory trial, known as OCEAN, following its 2021 accelerated approval of Pepaxto (melphalan flufenamide) as a fifth-line therapy for multiple myeloma.
If pharma advertising had a fantasy football league, Pfizer would be crushing the competition. A dive into the National Football League’s TV commercial buys across early season games by iSpot shows a hefty lead with its Covid-19 Comirnaty vaccine ads.
More than 175 million impressions with $9.5 million in media spending put Pfizer in the top spot with a 65% share of voice across NFL pharma spending, according to the real-time TV ad tracker. In a distant second place is Bristol Myers Squibb’s Opdivo with 44 million impressions, $5.2 million in spending and a 16% share, followed by BMS’ Zeposia with 31 million impressions, $3.3 million in media buys and an 11% share.
Unlock this story instantly and join 150,600+ biopharma pros reading Endpoints daily — and it’s free.
Wendy Lund is going home – to WPP, that is. Lund is leaving the Merck women’s health spinoff Organon where she is chief communications officer for a newly created role as WPP chief client officer for health and wellness. Before Organon, Lund led GCI Group, a WPP healthcare communications agency, as CEO for 11 years.
Lund joins WPP’s group of global client leaders who act as a single point of contact or entry for clients with WPP brands and businesses inside the holding company. and in this case, for the WPP health and wellness business.
Unlock this story instantly and join 150,600+ biopharma pros reading Endpoints daily — and it’s free.
Takeda has managed to offload an experimental cancer drug that’s been sitting on the shelf — in exchange for $7 million in cash plus milestones.
Puma Biotechnology is the buyer for alisertib, an aurora kinase A inhibitor, which it now plans to develop as a treatment of metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer and small cell lung cancer.
Unlock this story instantly and join 150,600+ biopharma pros reading Endpoints daily — and it’s free.
The fallout of the Covid-19 pandemic is still playing out more than two and a half years after it began, and the newest effects impacting the biopharma industry fall directly on real estate.
Real estate developer BXP said Wednesday that it acquired a building in Cambridge, MA from Biogen for $592 million. The building, located at 125 Broadway in Cambridge, MA, is in Cambridge’s biotech hub in Kendall Square, home to other companies such as Thermo Fisher Scientific and Moderna.
Unlock this story instantly and join 150,600+ biopharma pros reading Endpoints daily — and it’s free.
Lonza has opened the doors to an expansion at one of its primary locations.
The expansion occurred at Lonza’s highly potent API (HPAPIs) suite at its core manufacturing site in the city of Visp, Switzerland. The expansion adds room for the development and manufacturing of Lonza’s ADC products, which are becoming more popular.
“We expanded our HPAPI capabilities at our Visp site to meet the growing demand for ADCs. This demand is driven by the need for improved anticancer therapeutics with fewer side effects. Although every component of the ADC is essential to its therapeutic activity, the payload is the one that kills cancer cells.
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
© Endpoints Company 2022
If you’re already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.
We’ll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWS Daily at 11:30 AM ET
EARLY EDITION Daily at 7:15 AM ET
ENDPOINTS PHARMA Daily at 2 PM ET
ENDPOINTS MARKETING RX Tue at 2 PM ET
ENDPOINTS FDA+ Wed at 2 PM ET
ENDPOINTS MANUFACTURING Thu at 2 PM ET
ENDPOINTS WEEKLY Sat at 6 AM ET

source

Leave a Comment